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Mucopolysaccharidosis type II (MPS II; Hunter syndrome; OMIM 309900) is a rare lysosomal storage disease with
progressive multisystem manifestations caused by deficient activity of the enzyme iduronate-2-sulfatase. Disease-
specific treatment is available in the form of enzyme replacement therapy with intravenous idursulfase (Elaprase®,
Shire). Since 2005, the Hunter Outcome Survey (HOS) has collected real-world, long-term data on the safety and
effectiveness of this therapy, as well as the natural history of MPS II. Individuals with a confirmed diagnosis of MPS
II who are untreated or who are receiving/have received treatment with idursulfase or bone marrow transplant can
be enrolled in HOS. A broad range of disease- and treatment-related information is captured in the registry and,
over the past decade, data from more than 1000 patients from 124 clinics in 29 countries have been collected.
Evidence generated from HOS has helped to improve our understanding of disease progression in both treated
and untreated patients and has extended findings from the formal clinical trials of idursulfase. As a long-term, global,
observational registry, various challenges relating to data collection, entry, and analysis have been encountered. These
have resulted in changes to the HOS database platform, and novel approaches to maximize the value of the information
collected will also be needed in the future. The continued evolution of the registry should help to ensure that HOS
provides further insights into the burden of the disease and patient care and management in the coming years.
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Randomized controlled clinical trials are the gold stand-
ard for assessing the safety and efficacy of new drugs.
However, they typically measure only the short-term
impact of therapies in limited, strictly controlled patient
populations, using standardized treatment protocols [1].
As a result, clinical data obtained in the real-world
setting over a longer period of follow-up in larger patient
groups are increasingly required to complement and
extend findings from clinical trials. This is particularly
true for rare diseases, where the number of patients
available to participate in trials is often small and the
natural disease course may be poorly defined or highly* Correspondence: dwhiteman@shire.com
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formation on disease course and treatment outcomes,
and there are now more than 600 rare disease registries
in Europe alone [3, 4].
One group of diseases for which patient registries have
been particularly valuable is the lysosomal storage
diseases (LSD). These are rare, inherited, progressive
disorders caused by defects in lysosomal function, and
they typically have a highly variable clinical course.
Patient registries have been established for a number of
LSD, including Gaucher disease, Fabry disease, Pompe
disease, and mucopolysaccharidosis types I, II, IV, and
VI [5–12], and have provided important insights into the
natural history of these conditions and the long-term
effects of specific therapies.
Mucopolysaccharidosis type II (MPS II; Hunter syn-
drome; OMIM 309900) is a rare X-linked disorderle is distributed under the terms of the Creative Commons Attribution 4.0
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Table 2 Registry endpoints
Primary endpoints
Safety of idursulfase
• Occurrence of infusion-related reactions and other adverse events
(including serious adverse events)
• Immunogenicity, as determined by time to first positive antibody
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[13–15] (see Table 1). The disease primarily affects males
(estimated incidence, 0.6–1.3 in 100,000 live male births)
although a small number of female patients have been
described [13, 15, 16]. Historically, management of MPS
II was palliative, although two treatment options,
enzyme replacement therapy (ERT) and hematopoietic
stem cell transplantation (HSCT), are currently available
[17, 18]. ERT with recombinant I2S (idursulfase,
Elaprase®, Shire, Lexington, MA, USA) became avail-
able in the USA in 2006 and in Europe in 2007, and
stabilizes many of the somatic signs and symptoms of
MPS II [18–22].
The Hunter Outcome Survey (HOS) was established
in 2005 and the data collected have been used to address
post-approval commitments relating to Elaprase. This
global, multicentre, longitudinal, observational registry
collects real-world data on the clinical presentation and
progression of MPS II, and the long-term safety and
effectiveness of intravenous ERT with Elaprase. Here, we
discuss the contributions that data collected in HOS
have made to our knowledge of MPS II and share
insights into the nature of this type of clinical study,
lessons learned during the past decade, and the new
challenges to be overcome in the future.
Registry design and objectives
HOS is a long-term open-ended global registry designed
to collect information on patients with MPS II based on
data obtained during routine patient visits and assess-
ments [12]. The registry is open to individuals with a
biochemically or genetically confirmed diagnosis of MPS
II, including those who are untreated, those who are
receiving treatment with Elaprase, and those who have
undergone HSCT. Patients receiving ERT with a productTable 1 What is mucopolysaccharidosis type II (MPS II)?
• First described in two brothers by Dr Charles A. Hunter in 1917.
• Caused by deficient activity of the lysosomal enzyme iduronate-2-
sulfatase (EC 3.1.6.13), which catalyses a step in the catabolism of the
glycosaminoglycans (GAG) dermatan sulfate and heparan sulfate. The
accumulation of these in tissues and organs throughout the body
contributes to the chronic, progressive, multisystemic manifestations of
MPS II [14, 15].
• The initial clinical signs and symptoms typically emerge within the first
few years of life and include recurrent respiratory infections, coarse
facial features, joint stiffness, otitis media, hearing loss, umbilical/inguinal
hernias, and hepatosplenomegaly [45].
• The severity of the disease spans a broad range. For clinical purposes,
patients are generally considered to fall into one of two categories
according to the presence or absence of cognitive impairment. All patients
will experience somatic disease manifestations, although progression may
be slower in individuals without cognitive impairment [14, 15]. About two-
thirds of patients will display progressive central nervous system involvement,
initially resulting in learning impairment and abnormal behaviour, followed by
the development of profound cognitive impairment [12].other than Elaprase are not eligible for inclusion. Writ-
ten informed consent is obtained from each patient,
their parents, or legal representative. Data from individ-
uals who are alive at HOS entry (prospective patients)
can be entered; where local regulations permit, informa-
tion from those who died before enrollment (historical
patients) is also collected.
A broad range of disease- and treatment-related infor-
mation is captured in the registry (both prospectively
and retrospectively), with the primary objective of moni-
toring the long-term safety and effectiveness of ERT
with Elaprase in patients with MPS II (registry endpoints
are shown in Table 2). Secondary objectives of HOS are
to elucidate the natural history of the disease in
untreated patients and to monitor dosing regimens of
Elaprase in treated patients. In addition, participating
patients and/or their parents can complete the Hunter
Syndrome Functional Outcomes for Clinical Under-
standing Scale (HS-FOCUS) questionnaire, which is
used to assess the impact of MPS II on patients’ daily
lives. The observational nature of the registry means that
there is no predefined sample size and that a hypothesis-
free approach is employed. As a result, any data analyses
are considered to be exploratory.
HOS is operational in many countries around the
world. The registry has grown significantly over the past
10 years, and as of January 2016, 1096 patients from 124
clinics in 29 countries have been enrolled (Fig. 1). Thisresponse (antibody level and isotype), antibody titre, isotype, and
neutralizing antibodies
Effectiveness of idursulfase
• Urinary glycosaminoglycan levels
• Growth parameters (height, weight, head circumference)
• Distance walked in the 6-min walk test
• Left ventricular mass index (calculated by echocardiography)
• Pulmonary function (measured by forced expiratory volume in 1 s
and forced vital capacity)
• Liver and spleen size (as estimated by palpation)
• Prevalence of cardiac- and pulmonary-related hospitalizations
• Deaths (including age at death and cause of death)
Secondary endpoints
• Evaluation of the natural history of MPS II (based on the following
signs and symptoms: hepatosplenomegaly, central nervous system
involvement, skeletal involvement, and signs and symptoms of
cardiac, pulmonary, and ear, nose, and throat involvement)
• Evaluation of dosing of idursulfase (prescribed dose, administered
dose, total infusion time, missed infusions, and reasons for missed
infusions)
• Scoring in five domains in the patient- and parent-reported versions
of the HS-FOCUS questionnaire
HS-FOCUS Hunter Syndrome Functional Outcomes for Clinical Understanding
Scale, MPS II mucopolysaccharidosis type II
AB
Fig. 1 Key facts about the Hunter Outcome Survey. a The global reach of HOS. Countries with active HOS sites are indicated in grey. b Number
of patients enrolled in HOS since 2005
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Fig. 2 Key landmarks in the history of HOS and associated publications
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MPS II, and HOS is the largest global source of data
from patients with the disease. As with all clinical
studies, each participating clinic has an Investigator
and the registry complies with all relevant regula-
tions and best practices for ethical conduct. Strategic
direction and long-term scientific planning are over-
seen by a Steering Committee, which comprises an
international group of physicians with expertise in a
range of different disciplines.
Achievements of HOS over the past decade
Understanding the clinical presentation and progression
of MPS II
Analyses of data from the large number of patients in
HOS have made a significant contribution to our under-
standing of the clinical presentation and progression of
the disease [12, 23–29] (Fig. 2). For example when the
registry was initiated, quantitative data about the timing
and prevalence of the clinical manifestations of MPS II
were limited. One of the first analyses therefore looked
at the time of symptom onset [12]. This demonstrated
that the median age of symptom onset was 1.5 years,
with otitis media and abdominal hernia the earliest pre-
senting clinical features [12], extending and validating
some of the early descriptive reports of patients with
MPS II in a larger sample of over 200 patients. This
information is particularly valuable because physicians
may care for only a small number of individuals with the
disease, if any, during their career.
The diagnosis of MPS II is challenging and often de-
layed because of the non-specific and highly variable
nature of the clinical presentation of the disease [30]. An
analysis of surgical history in prospective patients in the
registry revealed a distinct pattern of procedures that
was common in individuals with MPS II [28]. In particu-
lar, tympanostomy, inguinal hernia repair, and carpal
tunnel release were performed in a greater proportion of
the study population than in the general population, and
repeat operations for hernia repair and carpal tunnel re-
lease were common in patients with MPS II [28]. It is
hoped that knowledge of this characteristic pattern of
surgical procedures, together with a greater awareness of
the early signs and symptoms of the disease among phy-
sicians from different medical specialties, will help to
facilitate prompt diagnosis and management of patients
with MPS II.
Insights into patient management
The pivotal clinical trials demonstrated that idursulfase was
generally well tolerated, with a similar safety profile to that
reported for ERT in patients with other MPS [19, 21, 22],
and data from HOS have enabled these findings to be
extended [31–37]. In particular, an analysis of data from104 patients treated with idursulfase for at least 1 year
demonstrated that, of the 33 patients who had an infusion-
related reaction (IRR), the majority (28/33; 85%) experi-
enced their first IRR during the first 3 months of treatment.
In addition, most IRRs were mild or moderate in severity
and could be managed without interrupting treatment [33].
This information enabled the development of guidance on
the management of IRRs [33].
The broad age range of patients enrolled in the regis-
try also allowed an analysis to be performed of safety
and preliminary clinical outcomes in patients younger
than 6 years of age [37], extending knowledge beyond
that obtained from the clinical trials of idursulfase which
were restricted to individuals older than 5 years. No new
safety issues were identified, and the data suggested that
idursulfase has a beneficial effect on palpable liver size
[37]. These findings, together with data from subsequent
studies in young patients [22], have helped to make
idursulfase available to children younger than 6 years
old, permitting early initiation of treatment, which is im-
portant for patients with this progressive disease [38].
HOS has also provided useful information on the
safety and feasibility of home infusions with idursulfase.
This option, available in several countries, can help to
ease the burden of the disease and its management on
patients and their families [39]. A study of 59 individuals
who received home therapy for at least 12 months re-
ported that five IRRs occurred in two patients [32].
These IRRs were readily managed at home by either
slowing or stopping the infusion and by appropriate pre-
treatment with antihistamines. These findings enabled
the development of guidelines and an algorithm to facili-
tate the transition of patients with MPS II from receiving
therapy in a clinical setting to receiving infusions at
home [32]. The increasing number of treated patients
enrolled in the registry should lead to further key
insights into the safety and effectiveness of ERT with idur-
sulfase in the future. It should be noted that although
patients who have received HSCT are eligible for inclusion
in the registry, only a small number have been enrolled
(Fig. 1). In addition, the assessment of outcomes in these
patients is beyond the scope of HOS and so the safety and
effectiveness of HSCT in patients with MPS II have not
been assessed using data from the registry.
Finally, it is increasingly recognized in the field of rare
diseases that patient-reported outcomes and patient in-
volvement in research are important for facilitating
measurement of treatment benefits and quality of life
and for ensuring that the care provided is patient
centred [1, 3]. The HS-FOCUS questionnaire was devel-
oped to obtain insight into the effects of MPS II on the
daily lives of patients and their parents and/or caregivers
[40, 41]. HS-FOCUS data have been collected in HOS
since 2006, and it is hoped that this information will
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the daily lives of patients and their families and poten-
tially lead to improvements in patient care.
Challenges encountered in HOS
Data collection and analysis
Although patient registries provide valuable longitudinal
data from a large, broad patient population, it is import-
ant to take into account the differences between data
collected in a formal clinical trial and those collected in
a registry. HOS is non-interventional and is designed to
acquire ‘real-world’ data from individuals with MPS II
during routine clinical practice [12]. As a result, the
methods and techniques used for clinical assessments
and laboratory assays are not standardized across
participating clinics. In addition, the frequency of
follow-up visits may vary considerably between patients.
It is also important to note that the clinical assessments
performed for each patient may differ as a result of
variation in disease severity between patients and differ-
ences in the standards of care and resources between
countries. For example, there is no standard method that
is used in all countries for assessing the cognitive and
behavioral aspects of MPS II [42].
The multisystem, progressive nature of MPS II also
means that each patient typically undergoes numerous
clinical and biochemical assessments [43] and is often
seen by many different specialists, such as cardiologists,
neurologists and otorhinolaryngologists [18, 43]. These
specialists are not necessarily directly involved or familiar
with HOS, and the specialist clinical assessments and
investigations are not always performed at the same site
where data entry takes place or at routine visits with the
managing physician. The collection of complete, high-
quality, uniform data for all patients is therefore often
difficult and this can make data analyses particularly chal-
lenging. For example, it is not always possible to collect a
full set of longitudinal information for each patient. As a
result, the number of patients whose data can be used for
analysis varies depending on the clinical parameters of
interest and the time frame studied. There is also no
formal control group and so there are limitations associ-
ated with analyses of idursulfase treatment effects.
Although a number of untreated patients have been en-
rolled in the registry, differences in clinical characteristics,
the care received, the frequency of clinical visits, and the
availability of follow-up data mean that comparisons with
treated patients are not straightforward.
Several strategies have been introduced to help partici-
pating clinics to increase data completeness. These
include the provision of data entry support and improve-
ments to the HOS database platform to make it more
user-friendly. A set of key clinical core data variables
comprising the minimum data set that should ideally becaptured for each patient has also been identified and
clinics are asked to focus on collecting these data for
each of their patients. In addition, HOS will need to
continue to evolve to ensure that the data captured
accurately reflect current routine patient care in differ-
ent countries, as well as new developments in our
understanding of MPS II and its management. In the
future, it will be important to take advantage of techno-
logical advances in database functionality, for example to
allow the entry of items such as magnetic resonance
imaging scans, and to make sure that the database is up-
dated to capture results from new clinical assessments
and tools that are developed in the future. This should
help to ensure that the value of the data collected in the
registry and the analyses performed are maximized and
meet the demands of multiple stakeholders.Meeting regulatory requirements
As a condition of the marketing authorization for
Elaprase, regulatory agencies in European and other coun-
tries (including USA and Canada) required additional
long-term safety and effectiveness data in patients with
MPS II being treated with idursulfase. Data requirements
for specific long-term outcome measures have continued
to evolve over time and currently include assessments of
pulmonary and cardiovascular morbidity and mortality,
urinary glycosaminoglycan levels, and antibody levels.
It is important to note that there are a number of chal-
lenges associated with assessing these treatment out-
comes. For example, pulmonary function can be
assessed using forced vital capacity (FVC) testing and
the 6-min walk test (6MWT). However, these tests are
unsuitable for particular patient subgroups (e.g. those
under 5 years of age and individuals with progressive
cognitive impairment) and may not be performed as part
of routine patient visits [22, 38, 44]. This makes the
evaluation of treatment effects in these patients particu-
larly challenging. The progressive, multisystemic nature
of MPS II also means that it is often impossible to
collect full, clinically meaningful data sets for many
patients, particularly those with advanced disease. Fur-
thermore, baseline data are not available for a substantial
number of patients because of the voluntary, non-
interventional nature of the registry and because patients
may begin treatment many years before HOS entry. As a
result, it is difficult to demonstrate long-term treatment
effectiveness based on the information available in the
database and it is likely that new methods will need to
be developed and implemented to address this.Conclusions
Building on its primary objective of documenting the
long-term safety and effectiveness of idursulfase in
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mation on the clinical presentation and progression of
the disease, as well as its management. These are consid-
erable achievements, and the registry has provided
information on a larger, broader patient population than
has been, or could be, studied in formal clinical trials.
The multinational nature of HOS and the engagement
of experts in MPS II are key strengths of the registry
and will be essential to ensure that the registry continues
to provide valuable insight into the similarities and
differences in patient demographics and management
between countries.
A number of challenges will, however, need to be over-
come. As further developments are made in the manage-
ment of patients with this progressive disorder, HOS will
need to evolve to ensure that the data collected continue
to reflect current practice for patient management
accurately and can be used to evaluate the long-term
effects of treatment. Patient-reported outcomes are also
increasingly being recognized as having an important
role in complementing traditional clinical data when
assessing the value of treatment in rare diseases [1, 3];
therefore, the continued collection of data from the HS-
FOCUS questionnaire remains a priority. Achieving
further improvement in the quality and comprehensive-
ness of the data will remain an important goal, and new
initiatives to facilitate this are likely to be required. One
approach may be to enable direct data entry by patients
and/or their family members, although the feasibility
and potential risks of such an approach would need to
be considered carefully and discussed with all relevant
stakeholders. In addition, it is important to note that
idursulfase does not cross the blood–brain barrier and
so treatment of neurological aspects of the disease re-
mains challenging. For this reason, several novel
approaches are currently being investigated, with the aim
of improving the care of patients with MPS II and
neurological involvement in the future.
Over the next decade, the implementation of new
approaches to aid data collection and entry, and to en-
hance methods for the evaluation of treatment effects over
the long term, should help to ensure that the value of the
information collected in HOS is maximized. Ultimately,
this will help to ensure that this registry continues
to improve our understanding of MPS II and its
management in real-world clinical practice.
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